8 withdrawn. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Withdrawn 8 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution - Ehlers-Danlos Syndrome, Low Back Pain | Phase 3 | Withdrawn | Tulane University | 2026-10-05 | 2026-10-08 | |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Alnuctamab, Pomalidomide, Daratumumab - Multiple Myeloma | Phase 3 | Withdrawn | Celgene | 2024-05-03 | 2024-05-31 | |
| Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia Methylprednisolone, Heparin - COVID-19 | Phase 3 | Withdrawn | D'Or Institute for Research and Education | 2020-07-20 | 2021-08-11 | |
| Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma Daratumumab Only Product in Parenteral Dose Form - Multiple Myeloma | Phase 3 | Withdrawn | Grupo Cooperativo de Hemopatías Malignas | 2020-03-01 | 2021-07-09 | |
| The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy ART-123, Placebo Comparator - Placebo - Sepsis and Coagulopathy | Phase 3 | Withdrawn | Asahi Kasei Pharma America Corporation | 2019-07-01 | 2019-09-13 | |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma Lenalidomide - Multiple Myeloma, Neoplasms | Phase 3 | Withdrawn | Celgene | 2014-07-01 | 2018-04-10 | |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Placebo, Velcade and dexamethasone, Siltuximab, Velcade and dexamethasone - Multiple Myeloma | Phase 3 | Withdrawn | Centocor, Inc. | 2011-07-01 | 2013-01-28 |
Multiple Myeloma (5) · Recurrence (2) · Blood Protein Disorders (1) · COVID-19 (1) · Ehlers-Danlos Syndrome (1) · Hematologic Diseases (1) · Low Back Pain (1) · Neoplasms (1) · Paraproteinemias (1) · Respiratory Insufficiency (1) · Sepsis (1)
Cardiovascular Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Vascular Diseases (8) · Hematologic Diseases (7) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphoproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Neoplasms, Plasma Cell (5) · Blood Protein Disorders (4) · Neoplasms (4) · Paraproteinemias (4) · Pathological Conditions, Signs and Symptoms (4)
Dexamethasone (4) · Lenalidomide (3) · Bortezomib (2) · carfilzomib (2) · daratumumab (2) · ART123 (1) · Calcium Dobesilate (1) · Glucose (1) · Heparin (1) · Injections (1) · Lidocaine (1) · Methylprednisolone (1) · elotuzumab (1) · pomalidomide (1) · siltuximab (1)
Celgene (2) · Asahi Kasei Pharma America Corporation (1) · Centocor, Inc. (1) · D'Or Institute for Research and Education (1) · Grupo Cooperativo de Hemopatías Malignas (1) · Regeneron Pharmaceuticals (1) · Tulane University (1)
Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Czechia (2) · India (2) · South Korea (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2) · Argentina (1) · Austria (1) · Bulgaria (1) · Chile (1) · China (1)
David Fineberg, MD (1) · Eduardo M Rego, MD, PhD (1) · Jacques Courseault, MD (1) · Yasir Nagarwala, MD (1)
2023 (1), 2025 (1)